SEC Comment Letter for ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Oct 16, 2017
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Oct. 16, 2017 · CIK: 0001612940 · Accession: 0000000000-17-036583
AI Filing Summary & Sentiment
Letter
October 16, 2017 Smital Shah Chief Financial Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands ProQR Therapeutics N.V. Form 20-F for Fiscal Year Ended December 31, 2016 Filed March 31, 2017 File No. 001-36622Re: Dear Ms. Shah: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.
Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
October 16, 2017
Smital Shah
Chief Financial Officer
ProQR Therapeutics N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
ProQR Therapeutics N.V.
Form 20-F for Fiscal Year Ended December 31, 2016
Filed March 31, 2017
File No. 001-36622Re:
Dear Ms. Shah:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance